LEXICON PHARMACEUTICALS
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 dia... betes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.
LEXICON PHARMACEUTICALS
Industry:
Bioinformatics Biotechnology Medical Pharmaceutical
Founded:
1995-01-01
Address:
The Woodlands, Texas, United States
Country:
United States
Website Url:
http://www.lexpharma.com
Total Employee:
251+
Status:
Active
Contact:
281-863-3000
Email Addresses:
[email protected]
Total Funding:
448.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving Apache Microsoft Exchange Online
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2001-06-13 | Coelacanth | Coelacanth acquired by Lexicon Pharmaceuticals | 32 M USD |
Investors List
Invus
Invus investment in Post-IPO Equity - Lexicon Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Lexicon Pharmaceuticals
Invus
Invus investment in Post-IPO Equity - Lexicon Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Lexicon Pharmaceuticals
USAMRMC
USAMRMC investment in Grant - Lexicon Pharmaceuticals
U.S. Army Medical Research & Development Command
U.S. Army Medical Research & Development Command investment in Grant - Lexicon Pharmaceuticals
Sofinov Societe Financiere D'Innovation
Sofinov Societe Financiere D'Innovation investment in Post-IPO Equity - Lexicon Pharmaceuticals
Punk, Ziegel & Company
Punk, Ziegel & Company investment in Post-IPO Equity - Lexicon Pharmaceuticals
Bay City Capital
Bay City Capital investment in Post-IPO Equity - Lexicon Pharmaceuticals
BCM Technologies (BCMT)
BCM Technologies (BCMT) investment in Post-IPO Equity - Lexicon Pharmaceuticals
Official Site Inspections
http://www.lexpharma.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.37 K
- Host name: ec2-54-161-141-183.compute-1.amazonaws.com
- IP address: 54.161.141.183
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Lexicon Pharmaceuticals" on Search Engine
Lexicon Pharmaceuticals, Inc.
About Us. Who We Are Foundations in Science Leadership Team. Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to โฆSee details»
Lexicon Pharmaceuticals - Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockoutSee details»
Lexicon Pharmaceuticals, Inc.
Senior Vice President and Chief Medical Officer. Read Bio. Kenneth Kassler-Taub, MDSee details»
Lexicon Pharmaceuticals - Crunchbase Company Profile & Funding
About. Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease. The Woodlands, Texas, United States. โฆSee details»
Lexicon Pharmaceuticals, Inc. | LinkedIn
About us. Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has โฆSee details»
Lexicon Pharmaceuticals Provides Business and Pipeline
THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of โฆSee details»
Lexicon Pharmaceuticals Provides Business and Pipeline Update โฆ
THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of โฆSee details»
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
Mar 12, 2024 Lexicon is hoping for an approval that clears the drug to be used as an add-on to insulin therapy for adults with Type 1 diabetes mellitus and chronic kidney disease, โฆSee details»
Lexicon Pharmaceuticals, Inc. (LXRX) - Stock Analysis
6 days ago THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations โฆSee details»
Lexicon poaches BMS' Tom Garner as new commercial lead
Oct 10, 2023 Lexicon Pharmaceuticals spent years jumping and often falling over regulatory hurdles for its new heart drug Inpefa, but, after finally getting an FDA approval โฆSee details»
Lexicon Pharmaceuticals Inc (LXRX) Stock Price & News - Google
Lexicon Pharmaceuticals Inc. $1.70. May 1, 3:34:34 PM GMT-4 · USD · NASDAQ · Disclaimer. 1D. 5D. 1M. 6M. YTD. 1Y. 5Y. MAX. search Compare to. Tilray Brands Inc. โฆSee details»
Lexicon Announces Oversubscribed $250 Million Private โฆ
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (โLexiconโ) today announced it has entered into โฆSee details»
Lexicon Pharmaceuticals Putting The Pieces Together, But Much โฆ
Jan. 26, 2024 10:31 AM ET Lexicon Pharmaceuticals, Inc. (LXRX) Stock AZN, LLY 16 Comments. 2 Likes. Stephen Simpson. 19.52K Follower s. Summary. Lexicon โฆSee details»
Lexicon Pharmaceuticals, Inc.
Pioneering the future of pharmaceuticals with a unique application of gene science, Lexicon Pharmaceuticals discovers and develops innovative and precise medicines for โฆSee details»
Lexicon Pharmaceuticals, Inc. (LXRX) - Yahoo Finance
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.See details»
Lonnel Coats Retires as Chief Executive Officer and Board
3 days ago THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has โฆSee details»
Tom Garner Joins Lexicon as Senior Vice President and Chief
THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the โฆSee details»
Lexicon Pharmaceuticals - Funding, Financials, Valuation
$813.6M. in funding over 11 rounds. Their latest funding was raised on Mar 11, 2024 from a Post-IPO Equity round. Lexicon Pharmaceuticals is registered under the ticker โฆSee details»
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial โฆ
3 days ago THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results โฆSee details»
Lexicon CEO to retire in July after a decade By Investing.com
3 days ago THE WOODLANDS, Texas - Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) announced today that CEO Lonnel Coats will retire on July 7, 2024, marking his โฆSee details»